Blog

Rx Price Reforms: PART I: We Already KNOW what DOESN’T Work

When it comes to controlling costs for prescription drugs, everybody wants to get into the act this year. With so ...

Biosimilars: Reading FDA’s Tea Leaves

When biosimilars hit FDA, what will be the review criteria? Everyone cares, since so much is at stake. The market ...

From the President’s Desk

Those who know me will raise an eyebrow, even drop a jaw, at hearing of the evolution from solo-based consulting ...

Medical Devices: Next on the Chopping Block?

Folks may just waking up to the impact that health reform will have on their businesses. Not just doctors or ...